A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

Phase 3

Completed

• Conditions: Glabellar Frown Lines
• Interventions: Biological: Botulinum toxin, Type A; Other: 0.9% sterile, unpreserved saline

• Registration Number: NCT02334436
• Lead Sponsor: Evolus, Inc.

Brief Summary

The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult subjects

Detailed Description

Three hundred and twenty-four eligible subjects will be randomly assigned 3:1 to receive DWP-450 or placebo. Safety and efficacy will be assessed on Days 2, 7, 14, 30, 90, 120 and 150. The primary efficacy end point assesses the effectiveness of the DWP-450 against placebo on Day 30 in a superiority design.

Study Timeline

• Study Start: 2015-01
• Study First Submitted: 2015-01-06
• Study First Submitted QC: 2015-01-07
• Study First Posted: 2015-01-08
• Primary Completion: 2015-09
• Study Completion: 2015-12
• Disposition First Submitted: 2017-02-01
• Disposition First Submitted QC: 2017-03-20
• Disposition First Posted: 2017-03-21
• Results First Submitted: 2019-01-04
• Results First Submitted QC: 2019-02-02
• Results First Posted: 2019-02-27
• Status Verified: 2019-03
• Last Update Submitted: 2019-03-14
• Last Update Posted: 2019-03-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 324

Inclusion Criteria

• Subjects is an adult, of at least 18 years of age
• Subject is able to provide informed consent and comply with study instructions
• Subject has moderate to severe glabellar lines at maximum frown as assessed by the investigator using the GLS
• Subject has moderate to severe glabellar lines at maximum frown as assessed by the subject using the GLS
• Subject is willing and able to complete the entire course of the study

Read More

Exclusion Criteria

• Previous treatment with botulinum toxin of any serotype in any area within the last 6 months
• Previous treatment with any facial aesthetic procedure (e.g. injection with fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months
• Previous insertion of permanent material in the glabellar area
• Planned treatment with botulinum toxin of any serotype in any other body region during the study period
• Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area and the surrounding areas (including eye brow)
• Energy-based or cryo-therapy based treatment of facial muscles superior to the lateral canthus
• Any other planned facial aesthetic procedure during the trial period, superior to the level of the lateral canthus (subjects can continue with their usual skin care routine)
• Subjects who may not respond to 20 Units of botulinum toxin (e.g., inability to substantially lessen glabellar frown lines even by physically spreading them apart)
• Marked facial asymmetry
• Ptosis of eyelid and/or eyebrow, or history of eyelid and/or eyebrow ptosis
• History of facial nerve palsy
• Excessive dermatochalasis, deep dermal scarring, thick sebaceous skin
• Any active infection in the area of the injection sites
• Medical condition that may affect neuromuscular function (e.g., myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis)
• Evidence of recent alcohol or drug abuse
• Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study
• Pregnant or sexually active female subjects who are of childbearing potential and who are not willing to use an acceptable form of contraception
• Known allergy or hypersensitivity to botulinum toxin preparation
• Participation in another interventional clinical study within the last 30 days

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Botulinum toxin, Type A	Botulinum toxin, Type A	Botulinum toxin, Type A
Placebo	0.9% sterile, unpreserved saline	0.9% sterile, unpreserved saline

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject	Day 30	The primary efficacy end point assesses the effectiveness of DWP-450 against placebo on Day 30. The primary efficacy measure is a composite end point. Using the GLS scale, investigators and subjects will assess the glabellar lines at Day 0 and Day 30. A subject is a responder only if both the investigator and subject independently agree that a ≥2 improvement has occurred from Day 0 to Day 30.; GLS is scored: 0=none, 1=mild, 2=moderate, 3=severe.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject	Day 150	Secondary endpoint was the proportion of subjects classified as responders on Day 150. This was a composite endpoint based on both the Investigator and subject assessments of glabellar lines at maximum frown on the GLS; a subject was a responder only if both the Investigator and subject independently agreed that a ≥2 point improvement had occurred from Day 0 to 150 Day; GLS is scored: 0=none, 1=mild, 2=moderate, 3=severe.

Trial Locations

Locations (1)

The Clinical Testing Center of Beverly Hills; 🇺🇸 Beverly Hills, California, United States